BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+11.22%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.3B
AUM Growth
+$10.3B
(+14%)
Cap. Flow
+$826M
Cap. Flow
% of AUM
8.01%
Top 10 Holdings %
Top 10 Hldgs %
81.62%
Holding
101
New
12
Increased
23
Reduced
8
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$235M |
| 2 |
Summit Therapeutics
SMMT
|
$198M |
| 3 |
Alkermes
ALKS
|
$55.1M |
| 4 |
Revolution Medicines
RVMD
|
$52.5M |
| 5 |
Structure Therapeutics
GPCR
|
$44.5M |
Top Sells
| 1 |
CRISPR Therapeutics
CRSP
|
$22.3M |
| 2 |
argenx
ARGX
|
$22M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$17.6M |
| 4 |
TSVT
2seventy bio
TSVT
|
$12.3M |
| 5 |
Akero Therapeutics
AKRO
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IDEAYA Biosciences
IDYA
$2.15B
| $44.5M | 0.43% | 2,118,728 +1,056,605 | +99% | +$22.2M |
|
27
Nurix Therapeutics
NRIX
$714M
| $44.2M | 0.43% | 3,882,125 | – | – |
|
28
Roivant Sciences
ROIV
$8.15B
| $42.5M | 0.41% | 3,767,773 | – | – |
|
29
BioNTech
BNTX
$24B
| $39.3M | 0.38% | 368,923 +323,892 | +719% | +$34.5M |
|
30
Entrada Therapeutics
TRDA
$208M
| $32.7M | 0.32% | 4,865,819 | – | – |
|
31
Merus
MRUS
$4.98B
| $30.2M | 0.29% | 574,377 +350,877 | +157% | +$18.5M |
|
32
Praxis Precision Medicines
PRAX
$958M
| $29M | 0.28% | 689,488 +357,955 | +108% | +$15.1M |
|
33
Intellia Therapeutics
NTLA
$1.22B
| $25.1M | 0.24% | 2,675,674 +2,031,558 | +315% | +$19.1M |
|
34
Viridian Therapeutics
VRDN
$1.5B
| $24.4M | 0.24% | +1,744,406 | New | +$24.4M |
|
35
Monte Rosa Therapeutics
GLUE
$296M
| $22.2M | 0.22% | 4,916,095 | – | – |
|
|
VRNA
36
Verona Pharma
VRNA
$9.16B
| $21.2M | 0.21% | 223,843 | – | – |
|
37
Vaxcyte
PCVX
$4B
| $20.8M | 0.2% | 640,885 | – | – |
|
|
38
argenx
ARGX
$43.6B
| $20.8M | 0.2% | 37,760 -40,000 | -51% | -$22M |
|
|
VERV
39
DELISTED
Verve Therapeutics
VERV
| $19M | 0.18% | 1,691,530 | – | – |
|
40
Cerus
CERS
$251M
| $18.2M | 0.18% | 12,883,844 -6,467,243 | -33% | -$9.12M |
|
41
Disc Medicine
IRON
$2.07B
| $17.9M | 0.17% | 337,050 +260,000 | +337% | +$13.8M |
|
|
42
Akero Therapeutics
AKRO
$3.74B
| $17.3M | 0.17% | 324,630 -224,083 | -41% | -$12M |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $16.1M | 0.16% | +125,538 | New | +$16.1M |
|
44
Sera Prognostics
SERA
$123M
| $15.2M | 0.15% | 5,498,170 | – | – |
|
45
Arrowhead Research
ARWR
$3.05B
| $14.8M | 0.14% | +939,174 | New | +$14.8M |
|
46
Neurogene
NGNE
$264M
| $14.8M | 0.14% | 991,691 -494,509 | -33% | -$7.39M |
|
47
Dianthus Therapeutics
DNTH
$759M
| $14.7M | 0.14% | +789,759 | New | +$14.7M |
|
48
Celldex Therapeutics
CLDX
$1.47B
| $13.5M | 0.13% | 665,370 +417,726 | +169% | +$8.5M |
|
|
DBVT
49
DBV Technologies
DBVT
$264M
| $13.4M | 0.13% | 1,461,425 | – | – |
|
50
Xenon Pharmaceuticals
XENE
$2.98B
| $11.6M | 0.11% | 370,208 +22,800 | +7% | +$714K |
|